This study was approved by the Hebei Yanda Lu Daopei Hospital Ethics Committee and informed consent was obtained from all participants before any study procedures were conducted. It was organized as a retrospective review study and Figure 1 illustrates the research design.
A total of 3395 patients who had received allo-HSCT from January 2013 to December 2019 in this hospital were identified. The MRD of these patients was analyzed by two-tube, eight-color MFC panel.
Three groups of patients who underwent bone marrow (BM) or peripheral blood (PB) immunophenotyping for non-malignant diseases at Hebei Yanda Lu Daopei Hospital were also identified. The first group included 5256 participants and the presence of CD16 expression in granulocytes was determined. The second group included 2000 participants who were screened for natural killer (NK) or T-cells for further immunophenotype analysis of NK lymphoma. The third group included 1100 participants over 35 years of age with non-neoplastic diseases who underwent screening of plasma and B cells.
A total of 3395 patients who had received allo-HSCT from January 2013 to December 2019 in this hospital were identified. The MRD of these patients was analyzed by two-tube, eight-color MFC panel.
Three groups of patients who underwent bone marrow (BM) or peripheral blood (PB) immunophenotyping for non-malignant diseases at Hebei Yanda Lu Daopei Hospital were also identified. The first group included 5256 participants and the presence of CD16 expression in granulocytes was determined. The second group included 2000 participants who were screened for natural killer (NK) or T-cells for further immunophenotype analysis of NK lymphoma. The third group included 1100 participants over 35 years of age with non-neoplastic diseases who underwent screening of plasma and B cells.
